dupixenthcp.com domain details, DUPIXENT® (dupilumab) HCP Website
Description: DUPIXENT® (dupilumab) is a dual inhibitor of IL-4 and IL-13 signaling and is now approved for 4 indications. Serious adverse reactions may occur. Please see Important Safety Information and full Prescribing Information on website.
Domain rank: 3580436
Domain speed: Average (0.200 seconds at 0.503 MB/s)
Indexed URLs from dupixenthcp.com website (13)
The links in column here only counts links from external domains.
found date
links in
url title
url
2021-11-29
DUPIXENT® (dupilumab) HCP Website
2021-07-09
DUPIXENT® (dupilumab) HCP Website
www.dupixenthcp.com/?utm_source=google&utm_medium=cpc&utm_campaign=Brand_Core_Exact&utm_term=dupilumab_102325018-VQ6-18940097801 ...
2024-07-25
DUPIXENT® (dupilumab) HCP Website
2022-07-06
Contact a Field Representative | DUPIXENT® (dupilumab)
2021-02-09
DUPIXENT® (dupilumab) HCP Website
2021-07-18
DUPIXENT® (dupilumab) Efficacy Results in CRSwNP
2021-07-18
DUPIXENT® (dupilumab) in Adults with CRSwNP | HCP Website
2021-07-18
Contact a Field Representative | DUPIXENT® (dupilumab)
2021-07-18
DUPIXENT® (dupilumab) HCP Website
2021-07-18
Mechanism of Action in CRSwNP | DUPIXENT® (dupilumab)
2021-07-18
DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis That is Uncontrolled
2021-07-18
Eligible CRSwNP Patient Profiles | DUPIXENT® (dupilumab)
2021-07-18
DUPIXENT® (dupilumab) in Moderate-to-Severe Asthma | HCP